Metabolic / GLP-1

5-Amino-1MQ

A small-molecule selective NNMT inhibitor investigated in preclinical models for reducing methyl-group sequestration in adipose tissue and restoring NAD+/SAM balance.

Research consideration: Oral capsule. Small molecule, not a peptide. Dose stored in mcg for schema consistency (50,000–150,000 mcg = 50–150 mg).

Quick facts

Molecular weight

159 Da

Half-life

8 h

Frequency

daily

Admins / wk

Routes

Oral

Typical dose

50.0 mg–150 mg

Mechanism & positioning

A small-molecule selective NNMT inhibitor investigated in preclinical models for reducing methyl-group sequestration in adipose tissue and restoring NAD+/SAM balance.

Researched for: nicotinamide N-methyltransferase inhibition, adipocyte energy metabolism.

Calculate with this peptide

References

Neelakantan H et al., Biochem Pharmacol, 2018.

Related peptides in the Metabolic / GLP-1 class

Frequently asked questions about 5-Amino-1MQ

What is the typical research dose range for 5-Amino-1MQ?

5-Amino-1MQ is most commonly investigated at 50.0 mg–150 mg per administration, daily. Note: oral capsule, mg-scale. These values reflect documented research-stage protocols and are not medical recommendations.

What is the half-life of 5-Amino-1MQ?

5-Amino-1MQ has an approximate plasma half-life of 8 hours. Practical steady state is reached after roughly five half-lives — about 2 days under continuous administration.

How is 5-Amino-1MQ administered in research protocols?

Published research uses oral administration. No reconstitution required — see the profile notes for delivery details.

What vial sizes are commonly available for 5-Amino-1MQ?

Common stocked vial sizes are 100 mg. The 100 mg vial is the most-used default in published protocols.

Anything important to know about 5-Amino-1MQ before designing a protocol?

Oral capsule. Small molecule, not a peptide. Dose stored in mcg for schema consistency (50,000–150,000 mcg = 50–150 mg).